tiprankstipranks
Trending News
More News >
Catheter Precision (VTAK)
:VTAK
Advertisement

Catheter Precision (VTAK) AI Stock Analysis

Compare
477 Followers

Top Page

VTAK

Catheter Precision

(NYSE MKT:VTAK)

Rating:44Neutral
Price Target:
$3.00
▼(-0.66% Downside)
Catheter Precision's overall stock score is primarily impacted by its poor financial performance and valuation, with technical indicators also showing bearish trends. While corporate events provide some positive news, the financial and technical weaknesses are significant concerns.

Catheter Precision (VTAK) vs. SPDR S&P 500 ETF (SPY)

Catheter Precision Business Overview & Revenue Model

Company DescriptionCatheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
How the Company Makes MoneyCatheter Precision generates revenue primarily through the sale of its electrophysiology systems and related consumables. The company’s revenue model is based on a combination of direct sales to hospitals and healthcare providers, along with recurring revenue from the sale of disposable catheters and accessories used in procedures. Additionally, Catheter Precision may engage in strategic partnerships with medical institutions and technology firms to enhance its product offerings and expand its market reach, contributing to its overall earnings.

Catheter Precision Financial Statement Overview

Summary
VTAK's financial performance is concerning, with declining revenue, negative net income margins, and ongoing operational losses. The balance sheet shows moderate leverage but negative return on equity. Cash flow remains negative, indicating significant financial challenges.
Income Statement
20
Very Negative
The income statement reveals a significant decline in revenue from 2019 to 2024, with a negative revenue growth rate. Gross profit margin is positive, but both EBIT and net income margins are negative, indicating persistent operational losses. This suggests challenges in achieving profitability despite efforts to control costs.
Balance Sheet
40
Negative
The balance sheet highlights a moderately leveraged position with a debt-to-equity ratio that is manageable. However, the return on equity is negative due to continuing net losses, which is a concern for investor returns. The equity ratio shows a reasonable proportion of equity financing, suggesting some financial stability.
Cash Flow
30
Negative
Cash flow analysis shows ongoing negative free cash flow, indicating cash outflows that exceed inflows from operations. The operating cash flow to net income ratio is unfavorable, reflecting cash flow challenges. The company needs to improve operational efficiency to enhance cash generation.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue600.00K420.00K442.00K14.00K22.00K4.41M
Gross Profit554.00K378.00K412.00K-147.00K-1.54M-1.08M
EBITDA-14.85M-11.30M-15.11M-22.37M-25.85M-33.30M
Net Income-19.25M-16.64M-70.57M-26.86M-25.07M-36.05M
Balance Sheet
Total Assets25.56M27.77M30.74M16.84M21.04M33.44M
Cash, Cash Equivalents and Short-Term Investments1.71M2.87M3.56M15.86M15.04M23.91M
Total Debt15.06M1.79M372.00K124.17K2.26M4.88M
Total Liabilities19.01M16.01M9.54M7.58M7.37M12.29M
Stockholders Equity6.79M11.76M21.19M9.26M13.67M21.15M
Cash Flow
Free Cash Flow-7.66M-9.34M-20.70M-22.59M-27.89M-28.37M
Operating Cash Flow-7.65M-9.27M-20.62M-22.57M-27.63M-28.30M
Investing Cash Flow-10.00K-67.00K-61.00K21.00K3.80M15.93M
Financing Cash Flow8.12M8.65M8.39M23.36M14.96M21.69M

Catheter Precision Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.02
Price Trends
50DMA
4.26
Negative
100DMA
4.81
Negative
200DMA
6.23
Negative
Market Momentum
MACD
-0.30
Negative
RSI
43.90
Neutral
STOCH
28.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTAK, the sentiment is Negative. The current price of 3.02 is below the 20-day moving average (MA) of 3.26, below the 50-day MA of 4.26, and below the 200-day MA of 6.23, indicating a bearish trend. The MACD of -0.30 indicates Negative momentum. The RSI at 43.90 is Neutral, neither overbought nor oversold. The STOCH value of 28.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VTAK.

Catheter Precision Risk Analysis

Catheter Precision disclosed 78 risk factors in its most recent earnings report. Catheter Precision reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Catheter Precision Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.82B-0.16-39.78%2.19%21.38%-1.56%
50
Neutral
$8.34M-233.04%-76.61%73.25%
47
Neutral
$25.15M-262.03%2.65%70.21%
45
Neutral
$5.38M-440.77%-7.72%99.54%
44
Neutral
$3.88M-179.11%37.61%68.37%
42
Neutral
$8.99M-195.48%-40.47%96.14%
37
Underperform
$7.38M-101.49%-19.81%93.32%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VTAK
Catheter Precision
3.02
-32.51
-91.50%
NUWE
Nuwellis
5.22
-54.84
-91.31%
SINT
Sintx Technologies
3.49
-0.74
-17.49%
HIND
Vyome Holdings
11.51
-1,000.59
-98.86%
VVOS
Vivos Therapeutics
4.20
1.30
44.83%
HSCS
Heart Test Laboratories, Inc.
3.65
0.17
4.89%

Catheter Precision Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Catheter Precision’s LockeT Approved for UK Market
Positive
Aug 18, 2025

On August 18, 2025, Catheter Precision announced the approval of its suture retention device, LockeT, for commercialization in the United Kingdom. This approval marks a significant milestone for the company, enhancing its market presence in Europe following the CE Mark approval in May 2025. LockeT is designed to improve patient comfort and recovery, enabling earlier discharge after cardiac procedures, which aligns with the NHS’s efforts to reduce waiting lists. The partnership with distributor HC21 is expected to facilitate LockeT’s market entry and support healthcare systems in the UK.

Shareholder MeetingsStock Split
Catheter Precision Implements 1-for-19 Reverse Stock Split
Neutral
Aug 15, 2025

Catheter Precision, Inc. held its 2025 annual meeting of stockholders on July 25, 2025, where the proposal for a reverse stock split was approved. The company’s board of directors decided on a 1-for-19 reverse stock split, which became effective on August 15, 2025. This move reduced the number of issued and outstanding shares significantly but did not alter the total authorized capital stock. The reverse split aimed to consolidate shares while maintaining stockholder equity and voting power, with adjustments made to stock options and warrants accordingly.

Shareholder MeetingsStock SplitRegulatory Filings and Compliance
Catheter Precision Approves Reverse Stock Split Plan
Neutral
Jul 28, 2025

On July 25, 2025, Catheter Precision held its Annual Meeting of Stockholders, where six proposals were considered and approved, including the election of a director and several stock issuance proposals. A significant decision was the approval of a reverse stock split at a ratio of 1-for-19, effective August 15, 2025, aimed at maintaining the company’s compliance with NYSE American’s listing requirements. This reverse stock split will reduce the number of outstanding shares from approximately 23.3 million to 1.2 million, ensuring the company’s continued listing on its current exchange without altering stockholders’ equity percentage.

Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Catheter Precision’s LockeT Sales Surge in Q2 2025
Positive
Jun 13, 2025

Catheter Precision announced that its LockeT product sales for Q2 2025 are on track to be the highest to date, surpassing Q2 2024 sales by over $84,000. The company has secured a new distributor in Italy and is seeking additional distributors in Spain, Portugal, and the UK, aiming to expand its European footprint. Three U.S. hospitals are expected to issue significant purchase orders for LockeT by the end of 2025, indicating strong market interest. The CE Mark approval for LockeT facilitates its sales in Europe, and a live demonstration is scheduled in Italy to boost product awareness.

Private Placements and FinancingShareholder Meetings
Catheter Precision Approves Warrant Issuance to Ladenburg
Neutral
Jun 9, 2025

On June 5, 2025, Catheter Precision, Inc.’s Board of Directors approved a warrant issuance to Ladenburg Thalmann & Co., Inc. as partial compensation for services related to the company’s pipe financing closed on May 12, 2025. This warrant allows the purchase of 257,143 shares at $0.5424 per share, pending stockholder approval at the annual meeting on July 25, 2025. The warrant will expire on June 6, 2030, and neither it nor the underlying shares have been registered under the Securities Act of 1933.

Executive/Board Changes
Catheter Precision Announces CCO Departure and Leadership Change
Negative
Jun 6, 2025

On June 2, 2025, Catheter Precision, Inc. announced the discontinuation of employment for their Chief Commercial Officer, Marie-Claude Jacques. Executive Chairman and CEO David Jenkins will temporarily assume the role until a new replacement is found, which may impact the company’s commercial operations and leadership dynamics.

Private Placements and Financing
Catheter Precision Announces New Common Stock Offering
Negative
May 30, 2025

Catheter Precision has announced a new offering of common stock that will result in dilution for new investors. As of March 31, 2025, the net tangible book value per share was $(1.71), and after adjustments, it is expected to be $(0.95) per share. This represents an immediate increase in value for existing shareholders but a substantial dilution for new investors purchasing at the assumed offering price of $0.30 per share. The company may also raise additional capital, which could lead to further dilution.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 21, 2025